Navigation Links
China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results

CHANGCHUN, China and LOS ANGELES, Oct. 14 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or "the Company"), a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced its unaudited financial results for the second quarter of 2009 which ended June 30, 2009.

Revenues for the second quarter of 2009 were essentially flat at approximately $14.6 million compared to the second quarter of 2008, with a marginal increase due to an increase in revenue from its retail drug stores offset by a decrease in volume from its pharmaceutical wholesale business. Revenues from retail drug stores were $6.0 million, compared to $5.8 million for the same period in 2008, which included a 10.9% increase for existing same store sales. A broader product portfolio, in addition to increased marketing activities, contributed to the growth. During the quarter, the Company launched one new chain drug store in Tianjin.

"We believe our business during the first half of 2009 was impacted by customers waiting for specifics on the new healthcare reform plan. On August 18 the Chinese government issued China's Essential Drug List (EDL) which included 307 commonly used pharmaceuticals. These will be subsidized by the government to provide easier access to all citizens. China Yongxin distributes 295 products included on this list and we believe our Company will benefit from the government's efforts to boost domestic spending, in addition to the new healthcare reform which is gaining momentum," commented Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin. "We have added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province in the first half of 2009 and we expect this to drive market share gains and growth during the balance of this year."

Cost of goods sold for the second quarts receivable (229,403) -- Other receivable (196,580) (799,159) Advances to suppliers (2,289,358) 2,077,575 Prepaid expenses 99,406 (70,437) Inventory (69,939) (1,556,377) Increase / (decrease) in current liabilities: Accounts payable 1,768,564 1,342,605 Notes payable 552,449 -- Other payable 677,711 2,571 Accrued expense (107,245) -- Tax payable 706,368 857,194 Advances from customers (1,007,358) 1,047,628 Deferred revenue (86,541) (249,545) Net cash provided by operating activities 1,020,888 1,956,221 CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from minority interest shareholders -- 11,406 Additions to construction in progress (275,529) -- Purchase of property, equipment and intangible assets -- (2,626,220) Net cash used in investing activities (275,529) (2,614,813) CASH FLOWS FROM FINANCING ACTIVITIES Receipt of short term loan -- 1,964,749 Receipts of loan from non-related parties 256,843 -- Receipts of Loan from related parties -- (1,620,887) Net cash provided by financing activities 256,843 343,863 NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 1,002,201 (314,730) EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS 8,545 225,092 CASH AND CASH EQUIVALENTS, BEGINNING BALANCE 609,422 1,180,029 CASH AND CASH EQUIVALENTS, ENDING BALANCE $1,620,168 $1,090,389 SUPPLEMENTAL DISCLOSURES: Interest paid $71,126 $101,631 Income tax paid $19,097 $-- NON CASH TRANSACTION: Conversion of account receivable to note receivable $-- $841,686

SOURCE China Yongxin Pharmaceuticals, Inc.

er was approximately $11.9 million, yielding a gross profit of $2.7 million and gross margins of 18.6%, compared to $2.9 million in gross profit and a gross margin of 19.6% during the second quarter of 2008. The slight decrease in gross margins was primarily attributable to the slight increase in cost of goods sold.

Operating expenses for the three months ended June 30, 2009, were $1.5 million, compared to approximately $1.6 million in the same period in 2008. Selling expenses for the period decreased marginally to $0.2 million from the year ago period. The Company prudently managed utilities usage, transportation costs and sales people to effectively reduce selling expenses and maintain gross profit. General and administration expenses for the three months ended June 30, 2009 increased approximately 30.7% to $0.8 million, compared to $0.6 million in the same year ago period, with the majority of the increase related to auditing expenses.

Operating income for the second quarter of 2009 totaled approximately $1.2 million, a 9.0% decrease from the $1.3 million reported for the second quarter of 2008. Operating margins were 8.1% and 9.0% for the second quarter of 2009 and 2008, respectively.

For the second quarter of 2009, net income was approximately $1.0 million, a 44.8% increase from the $0.7 million reported during the second quarter of 2008. The increase was primarily related to the absence of a $0.2 million interest expense which occurred during the second quarter of 2008. Diluted earnings per share were $0.03 compared to $0.02 for the second quarter of 2009 and 2008 respectively, based upon 32.0 million and 32.1 million shares. The income tax was $0.5 million compared to $0.6 million in the second quarter of 2008 with an effective tax rate of 28.2% in the second quarter.

Six-Month Results

For the six months ended June 30, 2009, revenues decreased approximately 19.4% to $23.8 million compared to the same period in 2008. Gross profit was $4.9 million for the first six months of 2009, representing a decrease of 8.1% from the first six months of 2008. Gross margins were 20.8% for the first six months of 2009 compared to 18.2% for the same period in 2008.

Income from operations was $1.8 million for the first six months of 2009, representing a decrease of 27.6% over the first six months of 2008. Operating margins were 7.7% for the first six months of 2009 compared to 8.6% for the first six months of 2008. Net income decreased marginally to $1.5 million for the six months ended June 30, 2009 compared to the same period in 2008. Diluted earnings per share were $0.05 compared to $0.05 for the first six months of fiscal 2009 and 2008 respectively, based upon 32.0 million and 32.1 million shares.

Balance Sheet and Cash Flow

Cash and cash equivalents totaled $1.6 million on June 30, 2009, compared to $0.6 million on December 31, 2008, while the Company maintained a short-term loan payable of $2.2 million. Accounts receivable grew 17.2% to $7.1 million from $6.0 million on December 31, 2008. Days sales outstanding stood at 43 compared to 37 in the second quarter of last year. The Company had a current ratio of 1.8 to 1 on June 30, 2009 and stockholders' equity of $19.7 million. For the first six months of 2009, the Company generated $1.0 million in cash from operations versus $2.0 million for the same period in 2008.

Business Development

On March 9, 2009, China Yongxin formally launched its Electronic Diagnosis System. To date the Company has installed 20 systems in Yongxin chain drugstores, all located in Changchun, Jilin. The System enables its customers to remotely receive a medical diagnosis and conveniently purchase prescription drugs at the store. The Company is always working to improve the level of service it offers, and leverage its large and growing base of "Member" customers who are entitled to discounts, rebates and special offers. This strategy, in addition to selling a broader array of higher margin health, beauty and cosmetics products, has increased customer retention and improved revenue and profitability in this business segment.

Since the beginning of 2009, China Yongxin has signed 12 exclusive distribution agreements for Jilin province with several well-known Pharmaceutical Manufacturers including Tianjin Smith Kline & French Laboratones Ltd. As of June 30, 2009, China Yongxin has approximately 216 drugs with exclusive distribution rights in Jilin province. This portfolio is a key component of its long-term growth strategy to leverage the large distribution center and channels established to drive incremental future revenue growth. These agreements are typically one year in duration and renewable.

China Yongxin recently secured loans from local banks and rural credit unions totaling $2.9 million with terms ranging from 1 to 3 years and are renewable after the initial terms. These funds will be utilized to provide working capital for the Company's distribution segment as it capitalizes on new organic growth opportunities supported by the government's new healthcare initiative.

"With enhanced government support, specifically the commencement of China's $126 billion health care reform plan focused on providing a broader spectrum of healthcare services and pharmaceutical products to all Chinese residents, we are confident that our modernized logistic center and distribution channels, broad customer base of chain drugstores, extensive product portfolio, and committed management team will enable us to resume our growth momentum and capitalize on a long-term, secular growth opportunity," concluded Mr. Liu.

About China Yongxin Pharmaceuticals, Inc.

China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), a wholesale drug distributor. Its products include Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing pharmaceutical companies in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit .

Forward-Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

    For the Company:
     Mr. Sam Liu, COO
     China Yongxin Pharmaceuticals, Inc.
     Tel:   +1-626-581-9098

     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155

                           CONSOLIDATED BALANCE SHEETS
                    AS OF JUNE 30, 2009 AND DECEMBER 31, 2008

                                             June 30, 2009  December 31, 2008
    Current Assets:
    Cash and cash equivalents                   $1,620,168          $609,422
    Accounts receivable, net                     7,070,275         6,030,874
    Notes receivable                             1,561,462         1,334,078
    Other receivable, net                          552,549           356,573
    Advances to suppliers                        8,465,678         6,186,269
    Prepaid expenses                               245,832           345,686
    Inventory, net                               7,923,325         7,864,677
    Current assets of the discontinued
     operations                                         46                46
    Total Current Assets                        27,439,336        22,727,625

    Property and Equipment, net                  2,512,538         2,680,207

    Construction In Progress                     6,357,179         6,066,249

    Intangible Assets, net                          60,428            73,687
    Total Assets                               $36,369,481       $31,547,768


    Current Liabilities:
    Accounts payable                            $5,944,014        $3,255,148
    Accrued expenses & other payable             2,694,603         2,447,067
    Advances from customers                      1,570,322         2,580,894
    Taxes payable                                1,944,665         1,240,411
    Loans to related parties                       184,662           184,662
    Short-term loans payable                     2,221,276         1,967,185
    Deferred income                                186,861           273,753
    Current liabilities of the
     discontinued operations                       628,883           628,883
    Total Current Liabilities                   15,375,288        12,578,003

    Long term loan                               1,318,500         1,320,390

    Commitments and Contingency                         --                --

    Stockholders' Equity:
    Preferred stock, $0.001 par value;
     authorized; 5,000,000 shares issued
     and outstanding                                 5,000             5,000
    Common stock; $0.001 par value;
     authorized; 31,510,540 shares issued
     and outstanding as of June 30, 2009
     and 31,400,540 shares issued and
     outstanding as of December 31, 2008            31,621            31,401
    Additional paid in capital                     635,487           615,906
    Deferred consulting expense -
     issuance of warrants                               --           (72,815)
    Prepaid consulting - issuance of
     shares                                             --           (68,750)
    Receivable from a related party                (50,000)          (50,000)
    Statutory reserve                            2,050,992         1,841,241
    Other comprehensive income                   1,660,196         1,684,649
    Retained earnings                           10,818,845         9,563,803
    Non-controlling interest                     4,523,552         4,098,940
        Total Stockholders' Equity              19,675,693        17,649,375
    Total Liabilities and Stockholders'
     Equity                                    $36,369,481       $31,547,768


                              For the Three-Month       For the Six-Month
                                    Period                    Period
                                 Ended June 30,            Ended June 30,
                               2009         2008         2009         2008
    Net Revenues           $14,638,615  $14,580,500  $23,823,609  $29,574,097
    Cost of Goods Sold     (11,920,027) (11,723,541) (18,874,297) (24,190,231)
    Gross profit             2,718,588    2,856,959    4,949,312    5,383,866

    Operating Expenses:
    Selling expenses           763,290      963,352    1,583,452    1,724,373
    General and
     expenses                  767,160      587,915    1,521,874    1,113,315
    Total operating
     expenses                1,530,449    1,551,267    3,105,325    2,837,688

    Income From Operations   1,188,139    1,305,692    1,843,986    2,546,178

    Other Income
    Other income               706,758      600,205      794,555      834,140
    Other expense              (47,160)     103,634      (20,783)     (34,906)
    Interest income
     (expense)                  16,458     (225,005)       7,984     (227,112)
    Total other income         676,057      478,834      781,757      572,122

    Operating Income
     Before Income Tax and
     Non controlling
     Interest                1,864,196    1,784,526    2,625,743    3,118,300

    Provision for income
     tax                      (525,801)    (565,227)    (730,566)    (940,142)

    Net Income Before Non
     controlling Interest    1,338,394    1,219,299    1,895,177    2,178,158

    Non controlling
     interest                 (297,801)    (500,378)    (430,386)    (691,881)

    Net Income               1,040,594      718,921    1,464,791    1,486,277

    Other Comprehensive
    Foreign exchange
     translation gain          (42,017)     294,872      (18,340)     836,712

    Net Comprehensive
     Income                    998,577    1,013,793    1,446,451    2,322,989

    Earning per share
    Basic                        $0.03        $0.02        $0.05        $0.05
    Diluted                      $0.03        $0.02        $0.05        $0.05
    Weighted average
     number of shares
    Basic                   31,148,219   31,116,845   31,095,623   31,079,138
    Diluted                 32,048,219   32,144,356   31,995,623   32,106,649

             FOR THE SIX MONTH PERIODS ENDED JUNE 30, 2009 AND 2008

                                                   2009              2008
    Net Income attributable to the
     company                                    $1,464,791        $1,486,277
    Adjustments to reconcile net income
     to net cash provided by operating
    Depreciation and amortization                  152,845           167,869
    Stocks and warrants issued or to be
     issued for services                            61,750           141,566
    Amortization of prepaid & deferred
     consulting cost                               141,565
    Non-controlling interest                       430,386           691,881
    (Increase) / decrease in current
    Accounts receivable                         (1,048,523)       (3,183,428)
SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
(Date:10/9/2015)... -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today announced ... Society of Emergency Medicine (EuSEM) meeting to be held October ... the Lingotto Congress Centre in Turin, Italy ... medicine practitioners in the world with over 2000 delegates in ... previously announced phase 2 bunionectomy trial will also be included.  ...
(Date:10/9/2015)... October 9, 2015 El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... Award 2015, se ha otorgado a los doctores ... ™ , una compañía biofarmacéutica global con sede enSuiza, presentará el ...
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. ... focused on gastrointestinal and cardio-renal diseases, today announced ... candidate, tenapanor, will be presented at the 2015 ... findings will include measures of sustained response in ... blind, placebo-controlled, randomized Phase 2 trial. The meeting ...
Breaking Medicine Technology:
... ,, NEW YORK , Aug. 3 ITelagen, a ... it was selected by Manhattan ,s Physician Group (MPG) to host, ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... for staff members. , , ...
... PHILADELPHIA , Aug. 3 ... a safe, isotope-free alternative to traditional radiation therapy ... focus of 14 clinical research studies presented at ... Meeting.  According to Xoft, Inc., the clinical benefits ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic Foundation (AOF) ... Medical Education J. Michael Finley, DO, as the recipient of the 2015 W. ... impact on graduate medical education opportunities for osteopathic residents, and his dedication to ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... For ... breast cancer victims, survivors, and the ongoing effort to find a cure. At Beverly ... outlet for helping women in need. With their Bra Collection Campaign, Beverly Hills Physicians ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... A new ... Home Exam Aid, is now available online ( ) – just in time ... (CDC) says officially begins in October. However, for many in the U.S., the real ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save ... can cut the risk of dying in reported home fires in half. As part ... sure smoke alarms are property installed and maintained. , Half of home fire deaths ...
Breaking Medicine News(10 mins):
... Mass., April 22 Haemonetics Corporation announced today that it will host its ... 12:30 pm at its corporate headquarters in Braintree, Massachusetts.The agenda for the meeting ... 2010 Annual Operating Plan Review , Plasma ... , R&D Progress , , ...
... combination of herbal ingredients contained in the anti-oxidant LiverLife ... reduce allergic responses in children with Autism Spectrum Disorder.LAGUNA ... brunt of the chemical age, accumulating toxins that weaken ... LiverLife(TM) significantly lowers the immune response ...
... It,s not every day people have the opportunity to ... From April 1 through June 30, 2009, however, The ICEcard ... do just that.A durable plastic card the size of a ... ICEcard, lists a person,s full name, age, address and phone ...
... Community, Overcharging Employers and Driving Up Healthcare ... Health System (WPAHS) yesterday filed a complaint in ... hospital system, and Highmark, Inc., Pittsburgh,s dominant health ... to protect one another from competition," with the ...
... Highlight Data for its Two Newest Urological Products -CORONA, ... WPI ), a global leader in the development ... host and webcast a meeting for the investment community ... place in Chicago, Illinois, April 25-30, 2009. The company ...
... The American Society of Hypertension, Inc. (ASH) today ... hypertension and related cardiovascular disease -- the ASH Hypertension ... of allied health professionals and pharmaceutical sales representatives. While ... the educational needs of each of the intended target ...
Cached Medicine News:
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The unique RF-1501 optical design provides exceptional sensitivity in an incredibly compact instrument....
... RNA, Or Fluorescent Tags. Accurate quantitation of minute ... life science research. The RF-Mini 150 Fluorometer offers ... small as 1ng/ml of DNA specific Hoechst Dye. ... emission filters, the RF-Mini 150 can measure RNA ...
Medicine Products: